Related Experiment Video
Updated: Jul 16, 2026

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically
Published on: September 9, 2015
Dalbavancin: a novel antimicrobial
A Y Chen1, M J Zervos, J A Vazquez
1Wayne State University School of Medicine, Division of Infectious Diseases, Henry Ford Hospital, Detroit, MI 48202, USA.
Abstract:
The increasing incidence of serious infections because of Gram-positive pathogens and the rising cost in parenteral administration of antimicrobials has inspired the development of a novel antibiotic. Dalbavancin is the first once a week antibiotic with activity against a broad range of Gram-positive pathogens. A large multicentre, pivotal, Phase III clinical trial, which included 854 patients with complicated skin and skin structure infections, compared 1-2 doses of dalbavancin vs. linezolid. The results demonstrated non-inferiority and a comparable safety profile. With its unique pharmacokinetic profile, ease of use and excellent safety profile, dalbavancin should provide a valuable addition to the armamentarium used to treat infections because of Gram-positive cocci.
Insights
Dalbavancin offers a new, once-weekly treatment option for Gram-positive bacterial infections. A Phase III trial showed it is as effective and safe as linezolid for complicated skin infections.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Microbiology
Background:
- Rising incidence of serious Gram-positive bacterial infections.
- Increasing costs and challenges associated with parenteral antimicrobial administration.
- Need for novel antibiotics with improved dosing and efficacy.
Purpose of the Study:
- To evaluate the efficacy and safety of dalbavancin compared to linezolid.
- To assess dalbavancin as a novel treatment for Gram-positive infections.
- To determine the suitability of dalbavancin for complicated skin and skin structure infections.
Main Methods:
- A large, multicenter, pivotal Phase III clinical trial.
- Inclusion of 854 patients with complicated skin and skin structure infections.
- Comparison of 1-2 doses of dalbavancin versus linezolid.
Main Results:
- Dalbavancin demonstrated non-inferiority to linezolid.
- A comparable safety profile was observed between dalbavancin and linezolid.
- Dalbavancin showed broad-spectrum activity against Gram-positive pathogens.
Conclusions:
- Dalbavancin is a valuable addition to the treatment options for Gram-positive cocci infections.
- Its unique pharmacokinetic profile and ease of use enhance its therapeutic potential.
- Dalbavancin provides an effective and safe alternative to existing treatments.
Related Concept Videos
Antimicrobial Effectiveness
Antifungal Agents
Inhibitors of Gram-positive Cell Wall Synthesis
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Inhibitors of Bacterial DNA Synthesis
Inhibitors of Bacterial Protein Synthesis

